Kewajiban jangka dawa marang ekuitas: polyrizon-biotech.com (PLRZ)

The price trend for Polyrizon Ltd (PLRZ) demonstrates the 0.00 indicator. The business relies on the sterile transportation of nasal products through pharmacy channels. The development of antiviral barriers is independent of market cycles, exhibiting only slight winter seasonality. Despite local instability in Israel, a Western patent strategy guarantees the company stability and a reliable operational basis.

The development of barrier nasal sprays requires significant R&D investment, which is reflected in the long-term debt load chart. This indicator measures the reliance of Polyrizon Ltd (PLRZ) on external financing with maturities exceeding one year. The metric is calculated as the ratio of long-term loans to the issuer's equity. An increase in this value signals rising financial risks, while a stable figure confirms the resilience of the business model during expansion scaling.